Monocyte chemoattractant protein-1 - A major contributor to the inflammatory process associated with diabetes

Archives of Physiology and Biochemistry

Volumn 112, Issue 4-5, 2006, Pages 239-244

  Dragomir, Elena ^a   Simionescu, Maya ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Atherosclerosis; Diabetes; Inflammation; MCP 1; Signaling

Indexed keywords

GLUCOSE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ATHEROSCLEROSIS; DIABETES MELLITUS; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER;

EID: 33845907381     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450601094672     Document Type: Review

References (60)

1. Asakawa H, Miyagawa J, Hanafusa T, Kuwajima M, Matsuzawa Y. 1997. High glucose and hyperosmolarity increase secretion of interleukin-1 beta in cultured human aortic endothelial cells. J Diabetic Complications 11:176-9.
2. Beckman JA, Creager MA, Libby P. 2002. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-81.
3. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetes complications. Nature 414:813-20.
4. Charo IF, Taubman MB. 2004. Chemokines in the pathogenesis of vascular disease. Circ Res 95(9):858-66.
5. Chen S, Mukherjee S, Chakraborty C, Chakraborty S. 2003. High glucoseinduced, endothelin-dependent fibronectin synthesis is mediated via NF-κB and AP-1. Am J Physiol 284:C263-72.
6. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzeti A. 2003. The receptor RAGE as a progression factor amplifying arachidonate- dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070-7.
7. Dawson TC, Kuziel WA, Osahar TA, Maeda N. 1999. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143:205-11.
8. Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-86.
9. Dragomir E, Tarcol M, Manduteanu I, Voinea M, Simionescu M. 2006. Aspirin and PPAR-α activators inhibit MCP-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 44(6):440-9.
10. Feng L, Matsumoto C, Schwartz A, Schmidt AM, Stern DM, Spellman JP. 2005. Chronic Vascular Inflammation in Patients With Type 2 Diabetes. Diabetes Care 28:379-84.
11. Getz GS. 1993. Report on the workshop on diabetes and mechanisms of atherogenesis, Sept 17th and 18th, 1992, Bethesda, Maryland. Arterioscler Thromb 13:459-64.
12. Gibbons GH, Dzau VJ. 1994. The emerging concept of vascular remodeling. N Eng J Med 330:1431-8.
13. Golovchenko I, Goalstone ML, Watson P, Brownle M, Draznin B. 2000. Hyperinsulinemia enhances transcriptional activity of nuclear factor-κB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 87:722-4.
14. Graier WF, Grubenthal I, Dittrich P, Wascher TC, Kostner GM. 1995. Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 294:221-9.
15. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-81.
16. Hiroshi T, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama M. 2003. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Comm 305:122-8.
17. Ho FM, Liu SH, Liau CS, Huang PJ, Shiah SG, Lin-Shiau SY. 1999. Nitric oxide prevents apoptosis of human endothelial cells from high glucose exposure during early stage. J Cell Biochem 75:258-63.
18. Hsueh WA, Law RE. 1998. Diabetes is a vascular disease. J Investig Med 46:387-90.
19. Hunjoo H, Mi RY, Yoon JC, Masanori K, Hi BL. 2002. Role of high glucose-induced nuclear factor-B activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13:894-902.
20. Ihma CG, Parka JK, Honga SP, Leea TW, Chob BS, Kima MJ, Chac DR, Hunjoo H. 1998. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial. Cells Nephron 79:33-7.
21. Jiang Y, Beller DI, Frendl G, Graves DT. 1992. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148:2423-8.
22. Kannel WB, McGee DL. 1979. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 241:2035-8.
23. Kim JA, Berliner JA, Natarajan RD, Nadler JL. 1994. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 43:1103-7.
24. Laakso M. 1999. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48(5):937-42.
25. Li L, Sawamura T, Renier G. 2003. Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes 52:1843-50.
26. Libby P. 2000. Changing concepts of atherosclerosis. J Intern Med 247:349-58.
27. Lo I-C, Jun-Ming S, Meei JJ. 2005. Reactive oxygen species and ERK 1/2 mediate monocyte chemotactic protein-1-stimulated smooth muscle cell migration. J Biomed Sci 12:377-88.
28. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. 1998. Abnormalities in monocyte recruitment and cytokine expression in MCP-1-deficient mice. J Exp Med 187:601-8.
29. Manduteanu I, Dragomir E, Antohe F, Radulescu L, Simionescu M. 2003. Effect of enoxaparin on high glucose induced activation of endothelial cells. Eur J Pharmacol 477(3):269-76.
30. Mine S, Okada Y, Tanikawa T, Kawahara C, Tabata T, Tanaka Y. 2006. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Comm 344(3):780-5.
31. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G. 1998. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest 101:1905-15.
32. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, Yo Y, Matsumoto K, Nakamura T, Higaki J, Ogihara T. 1997. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 46:138-42.
33. Nathan DM. 1998. Some answers, more controversy, from UKPDS. Lancet 352:832-3.
34. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. 1991. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88:1121-7.
35. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787-90.
36. Nishizuka Y. 1995. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484-96.
37. Onuffer JJ, Horuk R. 2002. Chemokines, chemokine receptors and small molecule antagonists: recent developments. Trends Pharmacol Sci 23:459-67.
38. Pyorala K, Laakso M, Uusitupa M. 1987. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3(2):463-524.
39. Ramana KV, Friedrich B, Bhatnagar A, Srivastava SK. 2003. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells. FASEB J 17:315-17.
40. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. 2002. Activation of nuclear factor-κB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241-8.
41. Rossi D, Zlotnik A. 2000. The biology of chemokines and their receptors. Annu Rev Immunol 18:217-42.
42. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, Giesen PL, Nemerson Y, Taubman MB. 1997. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 272:28568-73.
43. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. 2006. MCP-1 is a potential player in the negative crosstalk between adipose tissue and skeletal muscle. Endocrinology 147:2458-67.
44. Shanmugam N, Reddy MA, Guha M, Natarajan R. 2003. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52:1256-64.
45. Sheetz MJ, King GL. 2002. Molecular understanding of hyperglycemia's adverse effects for diabetes complications. JAMA 288:2579-88.
46. Shin WS, Szuba A, Rockson SG. 2002. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160:91-102.
47. Simionescu M, Popov D, Sima A, Hasu M, Costache G, Faitar S, Vulpanovici A, Stancu C, Stern D, Simionescu N. 1996. Pathobiochemistry of combined diabetes and atherosclerosis studied on a novel animal model. The hyperlipemic- hyperglycemic hamster. Am J Pathol 148(3):997-1014.
48. Sowers JR, Stump CS. 2004. Insights into the biology of diabetic vascular disease: what's new? Am J Hypertens 17(11 Pt 2):2S-6S.
49. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. 2001. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis. Diabetes 50:851-60.
50. Taniyama Y, Griendling KK. 2003. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42(6):1075-81.
51. Temaru R, Urakaze M, Satou A, Yamazaki K, Nakamura N, Kobayashi M. 1997. High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy. Diabetologia 40:610-3.
52. Terkeltaub R, Boisvert WA, Curtiss LK. 1998. Chemokines and atherosclerosis. Curr Opin Lipidol 9:397-405.
53. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. 1998. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. Br Med J 316:823-8.
54. Weber C, Schober A, Zernecke A, Chemokines. 2004. Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease. Arterioscler Thromb Vasc Biol 24:1997-2008.
55. Wiener OD, Neilsen PO, Prestwich GD, Kirschner MW, Cantley LC, Bourne HR. 2002. PtdInsP3- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol 4:509-12.
56. Xu J, Wang F, Van Keymeulen A, Herzmark P, Straight A, Kelly K, Takuwa Y, Sugimoto N, Mitchison T, Bourne HR. 2003. Divergent signals and cytoskeletal assemblies regulate self-organizing polarity in neutrophils. Cell 114:201-14.
57. Yamamoto T, Eckes B, Krieg T. 2001. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 31:2936-41.
58. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. 2000. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1a loop. J Immunol 164:6174-9.
59. Yerneni KKV, Bai W, Khan BV, Medford R, Natarajan R. 1999. Hyperglycemia induced activation of nuclear transcription factor κB in vascular smooth muscle cells. Diabetes 48:855-64.
60. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. 1991. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-6.